The drug companies notified by the House Oversight Committee: AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva pic.twitter.com/bjEnOZR9Kv— TicToc by Bloomberg (@tictoc) January 14, 2019
Bagsværd, Denmark, 18 March 2019 - Novo Nordisk today announced that a settlement between Novo Nordisk and Teva Pharmaceuticals USA, Inc. (Teva) has been reached on the US patent litigation case for Victoza®(liraglutide). Consequently, Teva is licensed to launch a generic version of Victoza® as of 22 December 2023.
Under certain circumstances Teva could launch a generic version of Victoza® earlier, but not before 22 March 2023, unless the Victoza® patents are no longer in force or there is another generic version of Victoza® on the market. If Novo Nordisk is granted six months paediatric extension for Victoza®, all above-mentioned timelines will be extended by six months. All other terms of the agreement are confidential.
The agreement is subject to review by the US Federal Trade Commission and the US Department of Justice.
"This settlement reflects the comprehensive US patent portfolio for liraglutide. Novo Nordisk will continue to defend our broad intellectual property portfolio for innovative drugs against challenges," said Jesper Brandgaard, executive vice president and head of Biopharm and Legal Affairs of Novo Nordisk.
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 80 countries and markets its products in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube
Source>>
********************************************************************************
::::WARNING::::
VictozaThe injectable Type 2 diabetes drug Victoza works by stimulating insulin production. It belongs to a class of drugs called GLP-1 mimetics. Studies link Victoza to pancreatitis, thyroid cancer and pancreatic cancer.
*Please seek the advice of a medical professional before discontinuing the use of this drug.
Kilder: 👉
https://www.radio24syv.dk/programmer/24syv-nyheder/19638569/nyheder-0700-19-10-2017
http://www.dr.dk/nyheder/penge/eksperter-giver-novo-nordisk-diabeteshaab-groent-lys-i-usa
http://www.euroinvestor.dk/nyheder/2017/09/29/novo-sydbank-rigtig-positive-nyheder-noget-af-det-var-ventet-ny/13681528
http://www.verdensalt.dk/2016/11/feel-bern-sanders-gar-i-flsket-pa-novo.html
http://www.euroinvestor.dk/nyheder/2017/11/17/novo-analytikere-konkurrents-godkendelse-oeger-konkurrencen/13712793
http://www.euroinvestor.dk/nyheder/2017/11/01/novo-ceo-semaglutid-er-en-noeglemulighed-for-os/13700803
http://www.euroinvestor.dk/nyheder/2017/09/29/novo-fiasp-godkendt-i-usa/13681488
http://borsen.dk/nyheder/virksomheder/artikel/1/346112/novo_nordisk_faar_godkendt_nyt_haemofilimiddel_i_usa.html
https://www.washingtonpost.com/news/wonk/wp/2017/11/24/the-trump-administration-is-taking-on-drug-prices-but-not-drug-companies/?utm_term=.18605b9dc1da
http://www.business.dk/medico/novo-nordisk-indgaar-forlig-paa-366-millioner-kroner
https://www.novonordisk.com/bin/getPDF.2126247.pdf
VIEW LAWSUIT INFORMATION--> HTTPS://WWW.DRUGWATCH.COM/VICTOZA/